Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · Real-Time Price · USD
24.11
-0.24 (-0.99%)
Jul 11, 2025, 1:47 PM - Market open
Vera Therapeutics Analyst Ratings
Total Analysts
8
Consensus Rating
Buy
Price Target
$64.63
Upside
+168.06%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Maintains $65 → $55 | Buy | Maintains | $65 → $55 | +128.12% | Jun 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $75 → $85 | Strong Buy | Maintains | $75 → $85 | +252.55% | Jun 2, 2025 |
| Wedbush | Wedbush | Hold Maintains $34 → $26 | Hold | Maintains | $34 → $26 | +7.84% | May 7, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $107 → $100 | Buy | Maintains | $107 → $100 | +314.77% | May 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $75 | Strong Buy | Initiates | $75 | +211.07% | May 5, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $77 → $71 | Buy | Maintains | $77 → $71 | +194.48% | Mar 4, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $59 → $61 | Strong Buy | Maintains | $59 → $61 | +153.01% | Feb 27, 2025 |
| Wolfe Research | Wolfe Research | Buy Initiates $49 | Buy | Initiates | $49 | +103.24% | Feb 4, 2025 |
| Wells Fargo | Wells Fargo | Buy Initiates $70 | Buy | Initiates | $70 | +190.34% | Nov 21, 2024 |
| Wedbush | Wedbush | Hold Maintains $30 → $38 | Hold | Maintains | $30 → $38 | +57.61% | Nov 8, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $72 → $75 | Buy | Maintains | $72 → $75 | +211.07% | Nov 5, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $56 → $64 | Strong Buy | Maintains | $56 → $64 | +165.45% | Oct 28, 2024 |
| Scotiabank | Scotiabank | Buy Initiates $60 | Buy | Initiates | $60 | +148.86% | Oct 16, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $107 | Buy | Reiterates | $107 | +343.80% | Oct 3, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $107 | Buy | Reiterates | $107 | +343.80% | Oct 1, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $107 | Buy | Reiterates | $107 | +343.80% | Sep 23, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.